Statin use and perimenopausal BMI determine the risk of incident diabetes mellitus in the postmenopause: Results of Palladia study

George Mavraganis; Nektaria Papanikola; Anastasia Angelopoulou; Aikaterini Stefanaki; Eleni Armeni; Stavroula Paschou; Valentina Anelli; Areti Augoulea; Kimon Stamatelopoulos; Irene Lambrinoudaki

doi:10.1530/endoabs.93.OC43

OC43

Prev Next

Section Contents Cite

Endocrine Abstracts (2023) 93 OC43 | DOI: 10.1530/endoabs.93.OC43

EYES2023 ESE Young Endocrinologists and Scientists (EYES) 2023 Oral communication 7: Diabetes, Obesity and Metabolism (7 abstracts)

Statin use and perimenopausal BMI determine the risk of incident diabetes mellitus in the postmenopause: Results of Palladia study

George Mavraganis ¹ , Nektaria Papanikola ² , Anastasia Angelopoulou ² , Aikaterini Stefanaki ² , Eleni Armeni ² , Stavroula Paschou ³ , Valentina Anelli ⁴ , Areti Augoulea ² , Kimon Stamatelopoulos ¹ & Irene Lambrinoudaki ²

Err

Author affiliations

¹University of Athens, Department of Therapeutics, Alexandra Hospital, Greece; ²University of Athens, 2nd Department of Obstetrics and Gynaecology, Aretaieio Hospital, Athens, Greece; ³School of Medicine, National and Kapodistrian University of Athens, Department of Clinical Therapeutics, Alexandra Hospital, Athens, Greece; ⁴University of Brescia, Department of Clinical and Experimental Sciences, Brescia, Italy.

Background: The menopausal transition has been associated with a heightened risk of cardiometabolic complications, including new onset diabetes mellitus (NODM). Statin-use increases the NODM-risk in the general population, however, their impact on NODM-risk specifically in postmenopausal populations has not been adequately studied.

Objectives: To estimate the effect of statin-use at baseline on the risk of NODM in postmenopausal women.

Methods: The PALLADIA study, a large prospective cohort, consists of middle-aged women assessed in the Menopause Clinic of Aretaieio Hospital, Athens Greece. All women were reviewed for symptoms related to menopause and followed-up (FU) annually based on their risk factors. We included 473 postmenopausal women (median duration of FU, 10 years).

Results: The prevalence of cardiovascular risk factors at baseline and FU were as follows: smoking 26% vs 19.4%, diabetes mellitus 3% vs 9.9%, hypertension (HTN) 22.4% vs 29.6%, dyslipidemia 30.9% vs 46.9%, statin-use 16.7% vs 34.2%. NODM was identified in 38 women, while NODM±impaired fasting glycaemia was found in 44 women. The use of statin at baseline increased the risk for NODM in the univariable analysis (OR=3.58, 95%CI: 1.74–7.37); multivariable analysis showed that NODM-risk was associated with statin use at baseline (OR=4.5, 95%CI, 1.67–12.11) adjusted for age, BMI, HTN, smoking. The combination of statin-use/BMI was associated with a higher risk for NODM±hyperglycemia (OR=4.63, 95% CI, 1.80–11.90).

Conclusions: Our results indicate that the NODM-risk attibuted to the use of statins in the Greek cohort of PALLADIA is higher compared to the risk reported in previous studies. Amidst traditional cardiovascular risk factors, baseline BMI appears to be the factor mostly related with the future risk for dysglycemia. Further research is required to explore the pathogenetic mechanisms underlying these observations.